IM Therapeutics Presents Clinical Advances at Advanced Technologies and Treatments for Diabetes (ATTD)
WOBURN, MA – February 19, 2020 – ImmunoMolecular Therapeutics (“IM Therapeutics”), a drug development company focused on personalized therapies for autoimmune disease, will present its clinical work in type 1 diabetes at the Advanced Technologies and Treatments for Diabetes (ATTD) in Madrid, Spain on February 20, 2020.
Dr. Peter Gottlieb, MD, Chief Medical Officer, IM Therapeutics, is an invited faculty member at the ATTD 2020 conference which will showcase the latest innovations and research for treatment of diabetes. Dr. Gottlieb will make a presentation in the session, “Screening and Early Intervention in Type 1 Diabetes.” His talk is titled “Methyldopa for early intervention in type 1 diabetes” and will discuss the clinical demonstration of HLA DQ8 blockade as a therapeutic strategy for type 1 diabetes.
Using L-methyldopa, an FDA-approved drug, as a tool drug molecule in a Phase 1b study of new onset type 1 diabetes, results showed blocking of DQ8 antigen presentation was achieved in a dose-dependent manner. Furthermore, studies of DQ8 transgenic mice showed that the D-enantiomer, not previously studied as a drug, was at least 3 times more potent than L-methyldopa.
IM Therapeutics was founded by Drs. Aaron Michels and Peter Gottlieb based on their seminal research showing that blocking the action of certain HLA gene variants can prevent the autoimmune response.
About IM Therapeutics
IM Therapeutics is developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. Its lead drug, IMT-002, is directed at HLA DQ8 activity for treatment of type 1 diabetes. The Company is building a broad pipeline of drugs against HLA targets in autoimmune disorders including celiac disease. IMTherapeutics.com
About AATD
The International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) was established in 2008. The purpose of the ATTD meeting is to highlight innovative technologies in diabetes treatment. It brings together developers of new technologies with the diabetes professionals and caretakers as well as acquainting clinicians with techniques for new treatments. Distinguished international professionals discuss and disseminate information on the latest technologies and treatments in the field. ATTD 2020
Media Contact
IM Therapeutics
Greg Kading
gkading@imtherapeutics.com